MYOV News and Press, Myovant Sciences Ltd. From 12/10/21

Sumitovant Biopharma Highlights Significant Clinical, Regulatory and Commercial Achievements Across its Portfolio of Companies in the Second Quarter of FY2021 - Enzyvant, a wholly-owned subsidiary of Sumitovant, received FDA approval for RETHYMIC® (allogeneic processed thym...

BASEL, Switzerland, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, will participate in the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021. David Marek, Chief Executive Officer o...

Relugolix is approved and launched in two indications and could establish itself as a new Standard of Care. The inked 4.2 billion deal with top-class partner Pfizer verifies the blockbuster potential of Relugolix. Quarterly reports reflect initial sales success and combined with s...

BASEL, Switzerland and LONDON, United Kingdom, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Nancy Valente, M.D. as an independent member of the company...

Spirovant to Present SP-101 Data at the 2021 North American Cystic Fibrosis Conference PR Newswire PHILADELPHIA , Oct. 28, 2021 /PRNewswire/ -- Spirovant Sciences , a gene therapy company developing treatments and cures for inherited respiratory diseases incl...

Image source: The Motley Fool. Myovant Sciences Ltd. (NYSE: MYOV) Q2 2021 Earnings Call Oct 26, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Myovant Sciences Ltd. (MYOV) Q2 2021 Earnings Call Transcript

Myovant Sciences Ltd. (MYOV) Q2 2021 Earnings Conference Call October 26, 2021 08:30 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Dave Marek - Chief Executive Officer Lauren Merendino - Chief Commercial Officer Uneek Mehra - Chief Financial and Business Officer J...

Gainers: Inspira Technologies (NASDAQ:IINN) +54%, SeqLL (NASDAQ:SQL) +46%, Ocugen (NASDAQ:OCGN) +27%, Aziyo Biologics (NASDAQ:AZYO) +15%, Roivant Sciences (NASDAQ:ROIV) +14%. Losers: Evaxion Biotech (NASDAQ:EVAX) -14%, Kiromic BioPharma (...

Second fiscal quarter 2021 total revenues of $77.9 million; net product revenue from U.S. sales of ORGOVYX ® of $18.7 million and MYFEMBREE ® of $0.6 million Estimated 8,000 cumulative patients treated with ORGOVYX through September 2021, includ...

AAN,ABG,ADM,ARCC,ARCH,AUDC,BDN,CAJ,CEQP,CIT,CLS,CNC,CVLT,CZOO,DAN,ECL,ENTG,GBX,GE,GLW,GPK,HAS,HUBB,OTCPK:HYMLF,HZO,INMD,IVZ,JBLU,LLY,LMT,MMM,MMYT,MSCI,MYOV,OTCQX:NHYDY,NVS,ORAN,OXSQ,PCAR,PERI,PHM,PII,PJT,PNR,RTX,SHW,SPGI,SSTK,ST,TPB,TRTN,TRU,UBS,UPS,WM,XRX For Seeking Alpha's full earnings se...